ArticleImmunologic research2011
Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.
Article in Immunologic research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.BMC cancer · 2025Article
- Targeting myeloid-derived suppressor cells in the tumor microenvironment: potential therapeutic approaches for osteosarcoma.Oncology research · 2025Review
- Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.Inflammopharmacology · 2021Review
- Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.Scientific reports · 2020Article
- Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups.Nanoscale · 2018Article
- The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Endocrine-related cancer · 2017Review
- Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders.Experimental and therapeutic medicine · 2017Article
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.The Journal of clinical investigation · 2015Review
- Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Cancer immunology, immunotherapy : CII · 2014Article
- Clinical evaluation of systemic and local immune responses in cancer: time for integration.Cancer immunology, immunotherapy : CII · 2014Article
- Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.Journal for immunotherapy of cancer · 2013Review
- Update on the challenges and recent advances in cancer immunotherapy.ImmunoTargets and therapy · 2013Review
- Article
- Immunological monitoring of the tumor immunoenvironment for clinical trials.Cancer immunology, immunotherapy : CII · 2012Review
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.Journal of immunotoxicologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent findings in humans and numerous experimental models provide evidence of the important role of immune regulatory cells in cancer and various diseases. "Myeloid regulatory cells" (MRC) include myeloid-derived suppressor cells, regulatory dendritic cells, regulatory macrophages, and subsets of granulocytes that expand during pathologic conditions and that have the ability to suppress cellular immunity. A decrease in MRC population and/or activity has been shown to have positive immune-potentiating effects. Several clinical trials have thus been initiated with the goal of manipulating the expansion or activation of these cells and thereby improving patient immune responses. New data from our own and other laboratories recently revealed that ultralow noncytotoxic doses of certain chemotherapeutic drugs could up-regulate antitumor immunity by modulating the formation, differentiation, and/or function of MRC. This new phenomenon, termed "chemomodulation," allows for the regulation of the tumor microenvironment without the undesirable toxic effects associated with conventional chemotherapy. However, further studies are required before this new targeted therapy can find its way to patients with cancer.
Indexed as
Identifiers
21717082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.